VXRT - Everything You Need to Know About Vaxart and Its Potential Coronavirus Vaccine
Before the pandemic, most healthcare investors had probably never heard of the vaccine biotech Vaxart (NASDAQ: VXRT). At the end of 2019, Vaxart's market cap was a minuscule $16.9 million, a far cry from the nearly $700 million it has reached today. Because of the pandemic, however, Vaxart's stock exploded overnight when its COVID-19 vaccine candidate showed early indications of effectiveness.
As perhaps the least developed company in the race for a COVID-19 vaccine, Vaxart is a compelling opportunity for investors, and given its string of vaccine development successes so far, there's plenty of time to invest for growth.
Image source: Getty Images.